Abstract 3914
Background
Sarcoma is a rare disease affecting both bone and connective tissue and with over 100 pathologic entities, diagnosis can be difficult. Approximately one third of sarcoma patients however are characterised by recurrent genetic alterations mainly chromosomal translocations, which result in fusion genes, and gene amplifications. Fusion genes are highly useful diagnostic markers and are currently identified in the clinical setting using FISH/RT-PCR. Conversely, conclusive results cannot be achieved in up to 25% of fusion positive patients using these methods. Next generation sequencing (NGS) is a promising tool that can improve soft-tissue sarcoma diagnosis.
Methods
A novel sarcoma-specific NGS gene capture panel containing probes for 90 fusion genes and 7 genes with frequent copy number changes was designed, optimised and validated in order to improve fusion-positive sarcoma diagnosis. Genomic DNA was extracted from 92 well-characterised FFPE samples and libraries prepared using the KAPA Hyperplus kit (Roche) and hybridised using the SeqCap Hybridisation kit (Roche) and sequenced on a NextSeq platform (Illumina).
Results
Sarcoma specific translocations or gene amplifications were identified in 92 out of 94 cases giving the targeted gene panel a sensitivity of approximately 98% and specificity of 100% (Table).Table:
1717P Sarcoma tumour types and number of cases with structural variants or copy number variations detected
Soft Tissue Tumour Type | No. of cases | SV/CNV detected |
---|---|---|
Synovial Sarcoma | 25 | 25 |
Alveolar Rhabdomyosarcoma | 6 | 6 |
Well/Dedifferentiated Liposarcoma | 9 | 8 |
Intimal Sarcoma | 1 | 1 |
Desmoplastic Small Round Cell Tumour (DSRCT) | 2 | 2 |
Ewing’s Sarcoma | 11 | 11 |
Inflammatory Myofibroblastic Tumour | 2 | 2 |
Myxoid Liposarcoma | 10 | 10 |
Chondroid Lipoma | 1 | 1 |
Clear Cell Sarcoma | 4 | 4 |
Epithelioid Haemangioendothelioma | 2 | 1 |
Low-grade Fibromyxoid Sarcoma | 3 | 3 |
Nodular Fasciitis | 1 | 1 |
Alveolar Soft Part Cell Sarcoma | 1 | 1 |
Congenital Fibrosarcoma | 2 | 2 |
Solitary Fibrous Tumour | 2 | 2 |
Aneurysmal Bone Cyst | 1 | 1 |
BCOR-CCNB3 Sarcoma | 1 | 1 |
Extraskeletal Myxoid Chondrosarcoma | 5 | 5 |
Mesenchymal Chondrosarcoma | 2 | 2 |
Dermatofibrosarcoma Protuberans (DFSP) | 3 | 3 |
TOTAL | 94 | 92 |
Conclusions
To the best of our knowledge this is the first sarcoma-specific NGS panel validated in FFPE-derived genomic DNA. It is at least as sensitive and specific as the combination of FISH and RT-PCR and can be implemented in routine clinical diagnostic workflows. We are currently investigating whether fusion genes can be detected in plasma using ctDNA from 14 patients and results will be reported at the conference.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
David Gonzalez de Castro.
Funding
Sarcoma UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial
Presenter: Wonyoung Choi
Session: Poster Display session 1
Resources:
Abstract
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract